AR121302A2 - Conjugados de anticuerpos basados en eribulina y métodos de uso - Google Patents
Conjugados de anticuerpos basados en eribulina y métodos de usoInfo
- Publication number
- AR121302A2 AR121302A2 ARP210100339A ARP210100339A AR121302A2 AR 121302 A2 AR121302 A2 AR 121302A2 AR P210100339 A ARP210100339 A AR P210100339A AR P210100339 A ARP210100339 A AR P210100339A AR 121302 A2 AR121302 A2 AR 121302A2
- Authority
- AR
- Argentina
- Prior art keywords
- eribulin
- methods
- antibody
- drug
- drug conjugates
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 229940127121 immunoconjugate Drugs 0.000 title 1
- 239000000611 antibody drug conjugate Substances 0.000 abstract 3
- 229940049595 antibody-drug conjugate Drugs 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 239000003053 toxin Substances 0.000 abstract 2
- 231100000765 toxin Toxicity 0.000 abstract 2
- 108700012359 toxins Proteins 0.000 abstract 2
- 102000010451 Folate receptor alpha Human genes 0.000 abstract 1
- 108050001931 Folate receptor alpha Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- UFNVPOGXISZXJD-XJPMSQCNSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-XJPMSQCNSA-N 0.000 abstract 1
- 229960003649 eribulin Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describen toxinas enlazadoras y conjugados de anticuerpo-fármaco que se unen a antígenos diana de oncología humana tal como receptor de folato a y/o proporcionan actividad de fármaco anti-tubulina. Las toxinas enlazadoras y conjugados de anticuerpo-fármaco comprenden un resto de fármaco de eribulina y se pueden internalizar en células que expresan el antígeno diana. La descripción además se refiere a métodos y composiciones para utilizar en el tratamiento de cáncer mediante la administración de los conjugados de anticuerpo-fármaco proporcionados en la presente.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662302562P | 2016-03-02 | 2016-03-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR121302A2 true AR121302A2 (es) | 2022-05-04 |
Family
ID=58347964
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170100524A AR107787A1 (es) | 2016-03-02 | 2017-03-02 | Conjugados de anticuerpos basados en eribulina y métodos de uso |
ARP210100339A AR121302A2 (es) | 2016-03-02 | 2021-02-10 | Conjugados de anticuerpos basados en eribulina y métodos de uso |
ARP210100338A AR121301A2 (es) | 2016-03-02 | 2021-02-10 | Conjugados de anticuerpos basados en eribulina y métodos de uso |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170100524A AR107787A1 (es) | 2016-03-02 | 2017-03-02 | Conjugados de anticuerpos basados en eribulina y métodos de uso |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP210100338A AR121301A2 (es) | 2016-03-02 | 2021-02-10 | Conjugados de anticuerpos basados en eribulina y métodos de uso |
Country Status (34)
Country | Link |
---|---|
US (4) | US10548986B2 (es) |
EP (2) | EP3824909A1 (es) |
JP (5) | JP6599019B2 (es) |
KR (4) | KR102445255B1 (es) |
CN (4) | CN114191563A (es) |
AR (3) | AR107787A1 (es) |
AU (2) | AU2017225982B2 (es) |
BR (1) | BR112018067379A2 (es) |
CA (1) | CA3013791A1 (es) |
CL (3) | CL2018002456A1 (es) |
CO (1) | CO2018008667A2 (es) |
CY (1) | CY1124628T1 (es) |
DK (1) | DK3423105T3 (es) |
ES (1) | ES2880402T3 (es) |
HR (1) | HRP20211125T1 (es) |
HU (1) | HUE054726T2 (es) |
IL (2) | IL292946B1 (es) |
JO (3) | JOP20170053B1 (es) |
LT (1) | LT3423105T (es) |
MA (1) | MA45280B1 (es) |
MD (1) | MD3423105T2 (es) |
MX (4) | MX2018010562A (es) |
MY (1) | MY189113A (es) |
PE (3) | PE20181953A1 (es) |
PH (1) | PH12018501847A1 (es) |
PL (1) | PL3423105T3 (es) |
PT (1) | PT3423105T (es) |
RS (1) | RS62108B1 (es) |
RU (2) | RU2021125492A (es) |
SG (2) | SG11201806515RA (es) |
SI (1) | SI3423105T1 (es) |
TW (3) | TW202408592A (es) |
UA (1) | UA125024C2 (es) |
WO (1) | WO2017151979A1 (es) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006116592A2 (en) * | 2005-04-22 | 2006-11-02 | Morphotek, Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
WO2016208695A1 (ja) * | 2015-06-24 | 2016-12-29 | Jcrファーマ株式会社 | 血液脳関門を通過する抗ヒトトランスフェリン受容体抗体 |
KR20180020279A (ko) | 2015-06-24 | 2018-02-27 | 제이씨알 파마 가부시키가이샤 | Bdnf를 포함하는 융합 단백질 |
BR112019009316A2 (pt) | 2016-12-26 | 2019-08-06 | Japan Chem Res | anticorpo antirreceptor de transferrina humana, proteína de fusão, fragmento de dna, vetor de expressão, célula de mamífero, complexo de composto farmacologicamente ativo e de anticorpo antirreceptor de transferrina humana, usos do anticorpo antirreceptor de transferrina humana e da proteína de fusão, e, métodos para tratamento de um distúrbio do sistema nervoso central e de uma doença do sistema nervoso central que acompanha a doença de pompe, a síndrome de hurler ou a síndrome de hurler-scheie. |
IL288991B2 (en) | 2017-04-05 | 2023-12-01 | Harvard College | A macrocyclic compound and its uses |
US11498892B2 (en) | 2017-07-06 | 2022-11-15 | President And Fellows Of Harvard College | Fe/Cu-mediated ketone synthesis |
SG11201912342QA (en) | 2017-07-06 | 2020-01-30 | Harvard College | Synthesis of halichondrins |
US20230158141A1 (en) | 2017-11-08 | 2023-05-25 | Yafei Shanghai Biolog Medicine Science & Technolog Co., Ltd | Conjugates of Biomolecule and Use Thereof |
EP3710454B1 (en) | 2017-11-15 | 2024-01-03 | President And Fellows Of Harvard College | Macrocyclic compounds and uses thereof |
TW202015739A (zh) * | 2018-06-01 | 2020-05-01 | 日商衛材R&D企管股份有限公司 | 剪接調節抗體-藥物結合物及其使用方法 |
EP3801523A2 (en) | 2018-06-01 | 2021-04-14 | Eisai R&D Management Co., Ltd. | Methods of using splicing modulators |
CA3108754A1 (en) | 2018-08-06 | 2020-02-13 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and tubulin inhibitor |
AU2019409132A1 (en) * | 2018-12-21 | 2021-07-15 | Novartis Ag | Antibodies to PMEL17 and conjugates thereof |
CN110568121A (zh) * | 2019-07-11 | 2019-12-13 | 山东省药学科学院 | 一种艾日布林及含艾日布林的制剂中有关物质的检测方法 |
WO2021090062A1 (en) | 2019-11-07 | 2021-05-14 | Eisai R&D Management Co., Ltd. | Anti-mesothelin eribulin antibody-drug conjugates and methods of use |
CA3164797A1 (en) | 2019-12-23 | 2021-07-01 | Eisai R&D Management Co., Ltd. | Method of producing eribulin based antibody-drug conjugate |
CA3168654A1 (en) | 2020-01-22 | 2021-07-29 | Shanghai Senhui Medicine Co., Ltd. | Drug conjugate of eribulin derivative, preparation method therefor and application thereof in medicine |
CN113274507A (zh) * | 2020-02-20 | 2021-08-20 | 亚飞(上海)生物医药科技有限公司 | 靶向递送和激活的免疫刺激性偶联复合物的制备和用途 |
AU2021284401A1 (en) | 2020-06-05 | 2023-01-05 | Eisai R&D Management Co., Ltd. | Anti-BCMA antibody-drug conjugates and methods of use |
KR20220018954A (ko) * | 2020-08-07 | 2022-02-15 | 주식회사 피노바이오 | 데옥시사이티딘계 항암제 및 실릴 에테르 함유 링커를 포함하는 접합체 및 이의 용도 |
JP2023542497A (ja) * | 2020-09-11 | 2023-10-10 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 抗セルロプラスミン抗体及びその使用 |
BR112023005593A2 (pt) * | 2020-09-28 | 2023-05-09 | Navrogen Inc | Composição e uso de anticorpos anti-mesotelina alternativamente formatados para tratamento de câncer |
CA3195850A1 (en) * | 2020-10-18 | 2022-04-21 | May Kung Sutherland | Anti-msln binding agents, conjugates thereof and methods of using the same |
CN114560940B (zh) * | 2020-11-27 | 2023-07-14 | 缔码生物科技(武汉)有限公司 | 一种抗SIRPα兔重组单克隆抗体及其制备方法和应用 |
WO2022217022A1 (en) * | 2021-04-10 | 2022-10-13 | Profoundbio Us Co. | Folr1 binding agents, conjugates thereof and methods of using the same |
CN117295524A (zh) * | 2021-06-02 | 2023-12-26 | 百奥泰生物制药股份有限公司 | 药物偶联物及其用途 |
TW202310878A (zh) | 2021-07-22 | 2023-03-16 | 大陸商上海森輝醫藥有限公司 | 艾日布林衍生物的藥物偶聯物 |
EP4385522A1 (en) * | 2021-08-13 | 2024-06-19 | Kunshan Xinyunda Biotech Co., Ltd. | Microtubule inhibitor-based antibody-drug conjugate |
WO2023024949A1 (zh) * | 2021-08-24 | 2023-03-02 | 昆山新蕴达生物科技有限公司 | 一种由可断裂连接子偶联的抗体偶联药物 |
KR20240056587A (ko) * | 2021-09-16 | 2024-04-30 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | 항-her3 항체 약물 접합체, 이의 조성물, 및 이의 용도 |
WO2023055376A1 (en) * | 2021-09-30 | 2023-04-06 | Virtuoso Binco, Inc. | Multispecific antibodies for targeting cd47 and icam1 and methods of use thereof |
TW202317088A (zh) * | 2021-10-14 | 2023-05-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | 艾日布林衍生物的製備方法 |
CN116199740A (zh) * | 2021-12-01 | 2023-06-02 | 上海生物制品研究所有限责任公司 | 抗体药物偶联物及其用途 |
WO2023103854A1 (zh) * | 2021-12-09 | 2023-06-15 | 昆山新蕴达生物科技有限公司 | 一种亲和力改善的抗体-药物偶联物、其制备方法及应用 |
WO2023124963A1 (zh) * | 2021-12-27 | 2023-07-06 | 昆山新蕴达生物科技有限公司 | 一种可逆反应减少的抗体-药物偶联物,其制备方法及应用 |
WO2023143320A1 (zh) * | 2022-01-28 | 2023-08-03 | 博瑞生物医药(苏州)股份有限公司 | 用于制备抗体药物偶联物的连接子、化合物及用途 |
WO2023143319A1 (zh) * | 2022-01-28 | 2023-08-03 | 启德医药科技(苏州)有限公司 | 抗体药物偶联物、药物组合物及用途 |
WO2023155808A1 (zh) * | 2022-02-16 | 2023-08-24 | 苏州宜联生物医药有限公司 | 抗体-艾日布林或其衍生物的偶联物、其中间体、制备方法、药物组合物和用途 |
WO2023170247A1 (en) | 2022-03-11 | 2023-09-14 | Mablink Bioscience | Antibody-drug conjugates and their uses |
WO2023198079A1 (zh) * | 2022-04-12 | 2023-10-19 | 百奥泰生物制药股份有限公司 | 治疗her2阳性实体瘤的方法 |
TW202400243A (zh) | 2022-04-12 | 2024-01-01 | 日商衛材R&D企管股份有限公司 | 基於艾日布林的抗體–藥物軛合物及其使用方法 |
WO2024078612A1 (en) * | 2022-10-14 | 2024-04-18 | Genequantum Healthcare (Suzhou) Co., Ltd. | Linker-payload compound, conjugates and applications thereof |
CN117917248A (zh) * | 2022-10-20 | 2024-04-23 | 英诺湖医药(杭州)有限公司 | 酶裂解连接子及包含其的配体-艾瑞布林偶联物 |
Family Cites Families (223)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Noble hydrazonic history of anthracycline and methods for their preparation |
DE68913658T3 (de) | 1988-11-11 | 2005-07-21 | Stratagene, La Jolla | Klonierung von Immunglobulin Sequenzen aus den variablen Domänen |
ATE221379T1 (de) | 1991-05-01 | 2002-08-15 | Jackson H M Found Military Med | Verfahren zur behandlung infektiöser respiratorischer erkrankungen |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
US5622929A (en) * | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
WO1997023243A1 (en) | 1995-12-22 | 1997-07-03 | Bristol-Myers Squibb Company | Branched hydrazone linkers |
AU2063197A (en) | 1996-03-04 | 1997-09-22 | Massachusetts Institute Of Technology | Materials and methods for enhancing cellular internalization |
US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
PT954282E (pt) | 1997-01-16 | 2005-06-30 | Massachusetts Inst Technology | Preparacao de particulas para inalacao |
DE69907456T2 (de) | 1998-06-24 | 2004-03-25 | Advanced Inhalation Research, Inc., Cambridge | Grosse poröse partikel ausgestossen von einem inhalator |
US6019963A (en) | 1998-11-20 | 2000-02-01 | D.S.C. Products, Inc. | Deodorizing composition containing tea tree and eucalyptus oils |
US7109019B2 (en) | 1999-01-06 | 2006-09-19 | The Regents Of The University Of California | Gene cluster for production of the enediyne antitumor antibiotic C-1027 |
JP4868698B2 (ja) | 2001-05-02 | 2012-02-01 | パーデュー・リサーチ・ファウンデーション | マクロファージが仲介する疾患の治療および診断 |
US7265085B2 (en) | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycoconjugation methods and proteins/peptides produced by the methods |
US7696163B2 (en) | 2001-10-10 | 2010-04-13 | Novo Nordisk A/S | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7265084B2 (en) | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
US7795210B2 (en) | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US8008252B2 (en) | 2001-10-10 | 2011-08-30 | Novo Nordisk A/S | Factor VII: remodeling and glycoconjugation of Factor VII |
US7439043B2 (en) | 2001-10-10 | 2008-10-21 | Neose Technologies, Inc. | Galactosyl nucleotide sugars |
US7399613B2 (en) | 2001-10-10 | 2008-07-15 | Neose Technologies, Inc. | Sialic acid nucleotide sugars |
US7297511B2 (en) | 2001-10-10 | 2007-11-20 | Neose Technologies, Inc. | Interferon alpha: remodeling and glycoconjugation of interferon alpha |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
US7226903B2 (en) | 2001-10-10 | 2007-06-05 | Neose Technologies, Inc. | Interferon beta: remodeling and glycoconjugation of interferon beta |
US7179617B2 (en) | 2001-10-10 | 2007-02-20 | Neose Technologies, Inc. | Factor IX: remolding and glycoconjugation of Factor IX |
US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
US7125843B2 (en) | 2001-10-19 | 2006-10-24 | Neose Technologies, Inc. | Glycoconjugates including more than one peptide |
AU2003224644A1 (en) | 2002-02-27 | 2003-09-09 | The Government Of The United States Of America, Represented By The Secretary, Department Of Healtan | Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use |
DK1545613T3 (da) * | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
JP2004119755A (ja) | 2002-09-27 | 2004-04-15 | Alps Electric Co Ltd | 磁気検出素子及びその製造方法 |
US20040071540A1 (en) | 2002-10-15 | 2004-04-15 | Lucas Philip J. | Disposable/recyclable pallet system and method |
US20080025989A1 (en) | 2003-02-20 | 2008-01-31 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
EP1615945B1 (en) | 2003-04-09 | 2011-09-28 | BioGeneriX AG | Glycopegylation methods and proteins/peptides produced by the methods |
BRPI0414568A (pt) | 2003-09-18 | 2006-11-07 | Combinatorx Inc | combinações de drogas para o tratamento de neoplasmas |
US6997024B2 (en) | 2003-10-01 | 2006-02-14 | Truth Hardware Corporation | Pull door lock |
US20050148535A1 (en) | 2003-10-30 | 2005-07-07 | Lacasse Eric | IAP nucleobase oligomers and oligomeric complexes and uses thereof |
US8012944B2 (en) | 2003-10-30 | 2011-09-06 | Pharmascience Inc. | Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent |
CA2556027C (en) | 2004-02-12 | 2015-11-24 | Morphotek, Inc. | Monoclonal antibodies that specifically block biological activity of a tumor antigen |
US7117807B2 (en) | 2004-02-17 | 2006-10-10 | University Of Florida Research Foundation, Inc. | Dynamically modifiable polymer coatings and devices |
WO2006073419A2 (en) | 2004-04-01 | 2006-07-13 | Gang Zheng | Lipoprotein nanoplatforms |
CA2569003A1 (en) | 2004-05-07 | 2005-12-08 | Massachusetts Institute Of Technology | Methods and compositions for cancer treatment relating to brca1 brct domain recognition of phosphorylated bach1 |
EP2949652B1 (en) | 2004-06-03 | 2019-08-07 | Eisai R&D Management Co., Ltd. | Intermediates for the preparation of halichondrin B |
ES2579805T3 (es) | 2004-09-23 | 2016-08-16 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
JP2008522623A (ja) | 2004-12-09 | 2008-07-03 | エーザイ株式会社 | ハリコンドリンbアナログを使用した癌治療でのチューブリンアイソタイプのスクリーニング |
US20060148014A1 (en) | 2004-12-09 | 2006-07-06 | Sergei Agoulnik | Tubulin isotype screening in cancer therapy using hemiasterlin analogs |
EP2722051B1 (en) | 2005-07-07 | 2018-11-07 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus |
US8871720B2 (en) | 2005-07-07 | 2014-10-28 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus |
GB0515025D0 (en) | 2005-07-21 | 2005-08-31 | Novartis Ag | Organic compounds |
ES2468240T3 (es) | 2005-08-19 | 2014-06-16 | Endocyte, Inc. | Conjugados de ligando de múltiples fármacos |
EP1926757B1 (en) | 2005-09-14 | 2012-02-22 | UCB Pharma, S.A. | Antibody-comb polymer conjugate |
US8293726B2 (en) | 2005-12-02 | 2012-10-23 | Vianova Labs, Inc. | Treatment of cancer and other diseases |
US7901885B2 (en) | 2006-05-09 | 2011-03-08 | Dsm Ip Assets B.V. | Genes and markers in type 2 diabetes and obesity |
US20150030534A1 (en) | 2013-07-26 | 2015-01-29 | Rutgers, The State University Of New Jersey | Antibody cocktails for breast cancer radioimmunotherapy |
US20140037539A1 (en) | 2012-07-27 | 2014-02-06 | Rutgers, The State University Of New Jersey | Antibody cocktails for breast cancer radioimmunotherapy |
US8398956B2 (en) | 2007-01-11 | 2013-03-19 | Immunomedics, Inc. | In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents |
WO2008101231A2 (en) | 2007-02-16 | 2008-08-21 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
EP2489372A3 (en) | 2007-03-14 | 2013-01-02 | Endocyte, Inc. | Binding ligand linked drug delivery conjugates of tubulysins |
EP1977765A1 (en) | 2007-04-03 | 2008-10-08 | Diatos | Peptide prodrugs |
EP2200992B1 (en) | 2007-10-03 | 2014-02-26 | Eisai R&D Management Co., Ltd. | Intermediates and methods for the synthesis of halichondrin b analogs |
NZ584514A (en) * | 2007-10-19 | 2012-07-27 | Genentech Inc | Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates |
CN101884058B (zh) | 2007-10-30 | 2012-07-25 | 富士通株式会社 | 移动终端装置 |
WO2009117531A1 (en) | 2008-03-18 | 2009-09-24 | Seattle Genetics, Inc. | Auristatin drug linker conjugates |
EP2279267A4 (en) | 2008-03-27 | 2012-01-18 | Vascular Biosciences Inc | METHOD FOR IDENTIFICATION OF NEW THERAPEUTIC CANDIDATES VIA GENE EXPRESSION ANALYSIS IN VASCULAR DISEASES |
EP2282769A4 (en) | 2008-04-29 | 2012-04-25 | Abbott Lab | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES |
US20100260668A1 (en) | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
JP2011523628A (ja) * | 2008-04-30 | 2011-08-18 | イミュノジェン・インコーポレーテッド | 有効なコンジュゲートおよび親水性リンカー |
US9109026B2 (en) | 2008-06-03 | 2015-08-18 | Abbvie, Inc. | Dual variable domain immunoglobulins and uses thereof |
CA2726087A1 (en) | 2008-06-03 | 2009-12-10 | Tariq Ghayur | Dual variable domain immunoglobulins and uses thereof |
KR20110031369A (ko) | 2008-07-08 | 2011-03-25 | 아보트 러보러터리즈 | 프로스타글란딘 e2 이원 가변 도메인 면역글로불린 및 이의 용도 |
CN102149690A (zh) | 2008-09-12 | 2011-08-10 | 参天制药株式会社 | 含有具有导入了磺酸酯结构的苯基作为取代基的新型1,2,3,4-四氢喹喔啉衍生物的糖皮质激素受体激动剂 |
CN102300879A (zh) | 2008-12-04 | 2011-12-28 | 雅培制药有限公司 | 双重可变结构域免疫球蛋白及其用途 |
CN105254758A (zh) | 2009-03-05 | 2016-01-20 | Abbvie公司 | Il-17结合蛋白 |
US20140339088A1 (en) | 2009-03-09 | 2014-11-20 | Virginia Tech Intellectual Properties, Inc. | Dielectrophoresis methods for determining a property of a plurality of cancer cells |
CN102459347A (zh) | 2009-05-01 | 2012-05-16 | 雅培制药有限公司 | 双重可变结构域免疫球蛋白及其用途 |
US8686520B2 (en) * | 2009-05-29 | 2014-04-01 | International Business Machines Corporation | Spin-torque magnetoresistive structures |
UY32808A (es) | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
SG178419A1 (en) * | 2009-08-15 | 2012-04-27 | Genentech Inc | Anti-angiogenesis therapy for the treatment of previously treated breast cancer |
MX2012002651A (es) | 2009-09-01 | 2012-05-22 | Abbott Lab | Inmunoglobulinas de dominio variable doble y usos de las mismas. |
GB0917044D0 (en) | 2009-09-29 | 2009-11-18 | Cytoguide As | Agents, uses and methods |
PE20121531A1 (es) | 2009-10-15 | 2012-12-22 | Abbott Lab | Inmunoglobulinas con dominio variable dual |
UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
ES2633317T3 (es) | 2009-11-06 | 2017-09-20 | Plexxikon, Inc. | Compuestos y métodos para la modulación de quinasas, e indicaciones para ello |
US8203010B2 (en) | 2010-01-26 | 2012-06-19 | Eisai R&D Management Co., Ltd. | Compounds useful in the synthesis of halichondrin B analogs |
CA2794266C (en) | 2010-03-24 | 2020-09-08 | Ohio University | Compositions and methods for glucose transport inhibition |
US8710035B2 (en) | 2010-03-24 | 2014-04-29 | The University Of Chicago | Methods and compositions related to glucocorticoid receptor antagonists and breast cancer |
TWI615405B (zh) | 2010-05-14 | 2018-02-21 | 艾伯維有限公司 | Il-1結合蛋白 |
NZ604718A (en) | 2010-06-15 | 2015-01-30 | Genmab As | Human antibody drug conjugates against tissue factor |
UY33492A (es) | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
CN103298834A (zh) | 2010-08-03 | 2013-09-11 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
CA2809433A1 (en) | 2010-08-26 | 2012-03-01 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
US9089570B2 (en) | 2010-09-03 | 2015-07-28 | Tactical Therapeutics Inc | Compositions for treating cancers having acquired resitance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate |
EP2613810B9 (en) | 2010-09-07 | 2016-02-17 | Johannes Kepler Universität Linz | Biodegradable, water soluble and ph responsive poly(organo)phosphazenes |
WO2012065019A2 (en) | 2010-11-12 | 2012-05-18 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of p13k alpha |
WO2012065057A2 (en) | 2010-11-12 | 2012-05-18 | Exelixis, Inc. | Phosphatidylinositol 3-kinase inhibitors and methods of their use |
WO2012075361A2 (en) | 2010-12-02 | 2012-06-07 | Immunomedics, Inc. | In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents |
MX2013007332A (es) | 2010-12-21 | 2014-01-23 | Abbvie Inc | Inmunoglobulinas de dominio variable doble biespecificas de il-1 alfa y beta y su uso. |
US20120195900A1 (en) | 2010-12-22 | 2012-08-02 | Abbott Laboratories | Tri-variable domain binding proteins and uses thereof |
WO2012088302A2 (en) | 2010-12-22 | 2012-06-28 | Abbott Laboratories | Half immunoglobulin binding proteins and uses thereof |
US20140024539A1 (en) | 2011-02-02 | 2014-01-23 | Translational Genomics Research Institute | Biomarkers and methods of use thereof |
AU2012217728B2 (en) | 2011-02-15 | 2017-04-27 | Vaxiion Therapeutics, Llc | Therapeutic compositions and methods for antibody and Fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells |
US9597340B2 (en) | 2011-02-25 | 2017-03-21 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
WO2012119077A1 (en) | 2011-03-02 | 2012-09-07 | Morphotek Inc. | Co -administration of eribulin and farletuzumab for the treatment of breast cancer |
WO2012118978A1 (en) | 2011-03-03 | 2012-09-07 | The Regents Of The University Of Colorado, A Body Corporate | Methods for treating oncovirus positive cancers |
EP2681196B1 (en) | 2011-03-04 | 2015-09-09 | Life Technologies Corporation | Compounds and methods for conjugation of biomolecules |
US9066963B2 (en) | 2011-03-15 | 2015-06-30 | The University Of North Carolina At Chapel Hill | Methods of treating breast cancer with anthracycline therapy |
ES2731653T3 (es) | 2011-03-18 | 2019-11-18 | Eisai R&D Man Co Ltd | Métodos y usos para predecir la respuesta a la eribulina |
EP2508525A1 (en) | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
US9132131B2 (en) | 2011-04-21 | 2015-09-15 | Saint Louis University | Use of adenosine A3 receptor agonists for treatment of neuropathic pain |
MX371526B (es) | 2011-05-27 | 2020-01-31 | Ambrx Inc | Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales. |
KR20200128601A (ko) | 2011-05-27 | 2020-11-13 | 암브룩스, 인코포레이티드 | 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도 |
WO2012170640A1 (en) | 2011-06-07 | 2012-12-13 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for trail-drug combination therapy |
RU2617402C2 (ru) | 2011-06-10 | 2017-04-25 | Мерсана Терапьютикс, Инк. | Конъюгаты белок-полимер-лекарственное средство |
US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
PT2739649T (pt) | 2011-08-05 | 2018-01-03 | Bioasis Technologies Inc | Fragmentos de p97 com atividade de transferência |
CN104053645A (zh) | 2011-11-30 | 2014-09-17 | 阿方拉研究股份有限公司 | 用于制备(3r)-2,4-二-离去基团-3-甲基丁-1-烯的工艺 |
US9174956B2 (en) | 2011-12-16 | 2015-11-03 | Alphora Research Inc. | Process for preparation of 3-((2S,5S)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives and intermediates useful thereof |
JP2015502397A (ja) | 2011-12-23 | 2015-01-22 | ファイザー・インク | 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用 |
US9717803B2 (en) | 2011-12-23 | 2017-08-01 | Innate Pharma | Enzymatic conjugation of polypeptides |
WO2013097042A1 (en) | 2011-12-29 | 2013-07-04 | Alphora Research Inc. | 2-((2s,3s,4r,5r)-5-((s)-3-amino-2-hydroxyprop-1-yl)-4-methoxy-3-(phenylsulfonylmethyl)tetrahydrofuran-2-yl)acetaldehyde derivatives and process for their preparation |
TWI573792B (zh) | 2012-02-01 | 2017-03-11 | 歐陸斯迪公司 | 新穎治療劑 |
WO2013130093A1 (en) * | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
WO2013138371A1 (en) | 2012-03-12 | 2013-09-19 | Merrimack Pharmaceuticals, Inc. | Methods for treating pancreatic cancer using combination therapies comprising an anti-erbb3 antibody |
US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
CN104470535A (zh) | 2012-03-29 | 2015-03-25 | 阿尔托生物科学有限公司 | 用于治疗肿瘤的方法 |
IN2014MN02106A (es) | 2012-03-30 | 2015-09-11 | Alphora Res Inc | |
MX2014011925A (es) | 2012-04-02 | 2015-05-11 | Merrimack Pharmaceuticals Inc | Dosificacion y administracion de anticuerpos monoespecíficos y biespecíficos anti- igf 1r y anti erbb3. |
JP6239598B2 (ja) | 2012-05-15 | 2017-11-29 | ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. | 薬物複合体、複合体形成方法、およびその使用 |
KR20150035537A (ko) | 2012-05-15 | 2015-04-06 | 디아테크 온콜로지, 엘엘씨 | 종양 세포 분리/정제 프로세스 및 이의 사용 방법들 |
AU2013270686B2 (en) | 2012-06-07 | 2016-11-10 | Ambrx, Inc. | Prostate-specific membrane antigen antibody drug conjugates |
AU2013273489B9 (en) | 2012-06-08 | 2018-08-23 | F. Hoffmann-La Roche Ag | Mutant selectivity and combinations of a phosphoinositide 3 Kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer |
CN111499684A (zh) | 2012-06-19 | 2020-08-07 | Ambrx公司 | 抗cd70抗体药物结合物 |
US9220695B2 (en) | 2012-06-29 | 2015-12-29 | The Research Foundation For The State University Of New York | Polyenolic zinc-binding agents (pezbins) actively promote inactivation of cancer stem cells and potentiate cytotoxic anti-tumor drug substances |
WO2014005010A2 (en) | 2012-06-29 | 2014-01-03 | Nanostring Technologies, Inc. | Methods of treating breast cancer with gemcitabine therapy |
HUE048574T2 (hu) | 2012-07-12 | 2020-08-28 | Hangzhou Dac Biotech Co Ltd | Sejthez kötõdõ molekulák citotoxikus szerekkel képzett konjugátumai |
US20140069822A1 (en) | 2012-09-10 | 2014-03-13 | Antec Leyden B.V. | Electrochemical reduction of disulfide bonds in proteinaceous substances and electrochemical cell for carrying out such reduction |
WO2014047199A1 (en) | 2012-09-19 | 2014-03-27 | The Research Foundation For The State University Of New York | Novel prodrugs for selective anticancer therapy |
CN104968347A (zh) | 2012-10-04 | 2015-10-07 | Ab科学有限公司 | 马赛替尼用于治疗使用预测因素鉴别的患者亚群的癌症的用途 |
WO2014058317A1 (en) | 2012-10-10 | 2014-04-17 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Methods and means for predicting resistance to anti-cancer treatment |
WO2014063443A1 (zh) | 2012-10-22 | 2014-05-01 | Zhang Yuliang | 自冷式热力做功方法 |
EP2911699B1 (en) | 2012-10-23 | 2017-11-15 | SynAffix B.V. | Modified antibody, antibody-conjugate and process for the preparation thereof |
AU2013340449B2 (en) | 2012-11-05 | 2017-11-30 | Pfizer Inc. | Spliceostatin analogs |
US10131682B2 (en) | 2012-11-24 | 2018-11-20 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules |
CA2892817A1 (en) | 2012-12-03 | 2014-06-12 | Calithera Biosciences Inc. | Treatment of cancer with heterocyclic inhibitors of glutaminase |
TW201425336A (zh) * | 2012-12-07 | 2014-07-01 | Amgen Inc | Bcma抗原結合蛋白質 |
US9243058B2 (en) | 2012-12-07 | 2016-01-26 | Amgen, Inc. | BCMA antigen binding proteins |
EP2928503B1 (en) | 2012-12-10 | 2019-02-20 | Mersana Therapeutics, Inc. | Conjugates of auristatin compounds |
WO2014093394A1 (en) | 2012-12-10 | 2014-06-19 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
WO2014093640A1 (en) | 2012-12-12 | 2014-06-19 | Mersana Therapeutics,Inc. | Hydroxy-polmer-drug-protein conjugates |
US20150314007A1 (en) | 2012-12-21 | 2015-11-05 | Glykos Finland Oy | Linker-payload molecule conjugates |
US20150182634A1 (en) | 2012-12-28 | 2015-07-02 | Cody P. Coyne | Molecular Design and Chemical Synthesis of Pharmaceutical-Ligands and Pharmaceutical-Pharmaceutical Analogs with Multiple Mechanisms of Action |
WO2014113792A1 (en) | 2013-01-19 | 2014-07-24 | New York University | Hydrogen-bond surrogate peptides and peptidomimetics for p53 reactivation |
US9695153B2 (en) | 2013-01-19 | 2017-07-04 | New York University | Oligooxopiperazines for p53 reactivation |
US20140220112A1 (en) | 2013-02-01 | 2014-08-07 | Zoneone Pharma, Inc. | Transformation of drug cyclodextrin complex compositions into compositions of mixtures of lipid vesicle encapsulated drug and cyclodextrin drug complexes |
SG11201506014VA (en) | 2013-02-01 | 2015-08-28 | Zoneone Pharma Inc | Remote loading of sparingly water-soluble drugs into liposomes |
US9849193B2 (en) | 2013-02-08 | 2017-12-26 | University Of Louisville Research Foundation, Inc. | Nanoparticles for drug delivery |
EP2958568B1 (en) | 2013-02-22 | 2020-03-04 | University Of Houston | Phosphaplatins as neuroprotective agents |
RS59013B1 (sr) | 2013-03-13 | 2019-08-30 | Oncoceutics Inc | 7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-heksahidroimidazo[1,2-a]pirido[4,3-d]pirimidin-5(3h)-on za upotrebu u lečenju kancera |
WO2015073072A1 (en) | 2013-11-15 | 2015-05-21 | Oncoceutics, Inc. | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one |
US9376437B2 (en) | 2013-03-13 | 2016-06-28 | Oncoceutics, Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy |
JP6488276B2 (ja) | 2013-03-14 | 2019-03-20 | ユニバーシティ オブ フロリダ リサーチ ファウンデーション,インコーポレイティド | 天然化合物及び/又は食事を用いる癌の調節 |
US20140271923A1 (en) | 2013-03-14 | 2014-09-18 | Christopher Brian Reid | Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions |
US20160022829A1 (en) | 2013-03-14 | 2016-01-28 | Mersana Therapeutics, Inc. | Tubulysin compounds and conjugates thereof |
CN105358174B (zh) | 2013-03-15 | 2019-03-15 | 酵活有限公司 | 具细胞毒性和抗有丝分裂的化合物以及其使用方法 |
US9295731B2 (en) | 2013-04-01 | 2016-03-29 | Mark Quang Nguyen | Cleavable drug conjugates, compositions thereof and methods of use |
WO2014168721A2 (en) | 2013-04-12 | 2014-10-16 | Tufts Medical Center | Methods and systems for designing and/or characterizing soluble lipidated ligand agents |
EP2988786A4 (en) | 2013-04-22 | 2016-12-21 | Avelas Biosciences Inc | COMPOSITIONS AND METHODS OF USE FOR SELECTIVE DRUG DELIVERY |
GB2513405A (en) | 2013-04-26 | 2014-10-29 | Adc Biotechnology Ltd | Method of synthesising ADCs using affinity resins |
LT2991683T (lt) | 2013-05-02 | 2019-12-27 | Glykos Finland Oy | Glikoproteino arba glikano konjugatai su toksine medžiaga |
AU2014268086A1 (en) | 2013-05-15 | 2015-11-05 | Alphora Research Inc. | 3-((2S,5S)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives, their preparation and intermediates useful thereof |
GB201309807D0 (en) | 2013-05-31 | 2013-07-17 | Pharma Mar Sau | Antibody drug conjugates |
US20140363454A1 (en) | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Antibody-Drug Conjugates, Compositions and Methods of Use |
US11229711B2 (en) | 2013-06-06 | 2022-01-25 | Magenta Therapeutics, Inc. | Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use |
WO2014202773A1 (en) | 2013-06-20 | 2014-12-24 | Innate Pharma | Enzymatic conjugation of polypeptides |
JP6744212B2 (ja) * | 2013-06-21 | 2020-08-19 | イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. | ポリペプチドの酵素的結合 |
WO2014206466A1 (en) | 2013-06-26 | 2014-12-31 | Afg Technologies S.À.R.L | Screening, diagnosis, prognostication and treatment of ovarian cancer |
JP6511613B2 (ja) | 2013-07-03 | 2019-05-15 | サンド・アクチエンゲゼルシヤフト | ハリコンドリンBの大環状C1−ケト類似体の製造のための合成方法及び該方法に有用な中間体、例えば−SO2−(p−トリル)基を含有する中間体 |
WO2015017729A1 (en) | 2013-07-31 | 2015-02-05 | Virginia Tech Intellectual Properties, Inc. | Dielectrophoresis methods for determining a property of a plurality of cancer cells |
WO2015017034A1 (en) | 2013-08-02 | 2015-02-05 | Gourdie Robert G | Methods of treating a cancer through targeted disruption of alpha connexin 43-zonula occludens-1 (zo-1) interaction |
WO2015031673A2 (en) | 2013-08-28 | 2015-03-05 | Bioasis Technologies Inc. | Cns-targeted conjugates having modified fc regions and methods of use thereof |
EP3038634A4 (en) | 2013-08-28 | 2017-10-11 | AbbVie Stemcentrx LLC | Novel sez6 modulators and methods of use |
SG11201601424PA (en) | 2013-08-28 | 2016-03-30 | Stemcentrx Inc | Site-specific antibody conjugation methods and compositions |
US20150072021A1 (en) | 2013-09-09 | 2015-03-12 | British Columbia Cancer Agency Branch | Methods and Kits for Predicting Outcome and Methods and Kits for Treating Breast Cancer with Radiation Therapy |
WO2015038426A1 (en) | 2013-09-13 | 2015-03-19 | Asana Biosciences, Llc | Self-immolative linkers containing mandelic acid derivatives, drug-ligand conjugates for targeted therapies and uses thereof |
US20150093331A1 (en) | 2013-10-01 | 2015-04-02 | OncoLock Co., Ltd. | Biomarkers for breast cancer |
US9878049B2 (en) | 2013-10-09 | 2018-01-30 | The University Of Akron | High drug loading system to co-deliver anticancer drugs and nucleic acids for cancer therapy |
US9849191B2 (en) | 2013-10-11 | 2017-12-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
HUE046816T2 (hu) | 2013-10-11 | 2020-03-30 | Asana Biosciences Llc | Fehérje-polimer-gyógyszer konjugátumok |
ES2764833T3 (es) | 2013-10-11 | 2020-06-04 | The United States Of America Represented By The Sec Dep Of Health And Human Services | Anticuerpos contra TEM8 y su uso |
JP6684706B2 (ja) | 2013-10-21 | 2020-04-22 | ヘモシアー・リミテッド・ライアビリティ・カンパニーHemoShear, LLC | 腫瘍微細環境のための試験管内モデル |
EP3066102B1 (en) | 2013-11-04 | 2020-02-26 | Eisai R&D Management Co., Ltd. | Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin b |
US9457019B2 (en) | 2013-11-07 | 2016-10-04 | Deciphera Pharmaceuticals, Llc | Methods for inhibiting tie-2 kinase useful in the treatment of cancer |
AU2013404949B2 (en) | 2013-11-07 | 2018-10-18 | Deciphera Pharmaceuticals, Llc | Methods for inhibiting TIE2 kinase useful in the treatment of cancer |
EP3068401B1 (en) | 2013-11-15 | 2019-02-27 | Oncoceutics, Inc. | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, salts thereof and methods of use |
AU2014354643B2 (en) | 2013-11-27 | 2020-03-05 | Redwood Bioscience, Inc. | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate |
SG10201805024YA (en) | 2013-12-06 | 2018-07-30 | Eisai R&D Man Co Ltd | Methods useful in the synthesis of halichondrin b analogs |
WO2015095784A1 (en) | 2013-12-19 | 2015-06-25 | Luminus Biosciences, Inc. | Solid nanoparticle formulation of microtubule inhibitors with reduced ostwald ripening for oral administration |
EP3091970B1 (en) | 2014-01-10 | 2020-10-28 | Rgenix, Inc. | Lxr agonists and uses thereof |
CN114716555A (zh) | 2014-01-10 | 2022-07-08 | 博笛生物科技有限公司 | 靶向表达egfr的肿瘤的化合物和组合物 |
EP3092027A4 (en) | 2014-01-10 | 2017-09-06 | Atossa Genetics Inc. | Transpapillary methods and compositions for diagnosing and treating breast conditions |
CN109316605B (zh) | 2014-01-20 | 2023-07-14 | 博瑞生物医药(苏州)股份有限公司 | 叶酸受体结合配体-药物偶联物 |
CA3151947A1 (en) | 2014-02-03 | 2015-08-06 | Eidgenoessische Technische Hochschule Zuerich | Low molecular weight drug conjugates for binding to carbonic anhydrase ix |
CA2937034A1 (en) * | 2014-02-03 | 2015-08-06 | National Cancer Center | Anti-tissue factor monoclonal antibody |
EP2913064A1 (en) | 2014-02-26 | 2015-09-02 | celares GmbH | Branched drug-linker conjugates for the coupling to biological targeting molecules |
TW201617326A (zh) | 2014-03-06 | 2016-05-16 | Alphora研發股份有限公司 | (s)-1-((2r,3r,4s,5s)-5-烯丙-3-甲氧-4-(對甲苯磺醯甲基)四氫呋喃-2-基)-3-氨基丙-2-醇之結晶衍生物 |
BR112016020953A2 (pt) | 2014-03-13 | 2018-01-23 | Hoffmann La Roche | composto, kit, composição farmacêutica, uso de composto, método de tratamento e invenção |
US9260478B2 (en) * | 2014-04-04 | 2016-02-16 | Shanghui Hu | Potent and efficient cytotoxic peptides and antibody-drug conjugates thereof and their synthesis |
SG11201607795UA (en) | 2014-04-08 | 2016-10-28 | Methodist Hospital | Inos-inhibitory compositions and their use as breast cancer therapeutics |
WO2015160833A1 (en) | 2014-04-14 | 2015-10-22 | Endocyte, Inc. | Drug delivery conjugates for treating resistant cancer and for use in combination therapy |
WO2015161247A1 (en) * | 2014-04-17 | 2015-10-22 | Igenica Biotherapeutics, Inc. | Humanized anti-c16orf54 antibodies and methods of use thereof |
TWI695011B (zh) * | 2014-06-18 | 2020-06-01 | 美商梅爾莎納醫療公司 | 抗her2表位之單株抗體及其使用之方法 |
US9808528B2 (en) * | 2014-06-18 | 2017-11-07 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates and methods of using same |
EP3069734A1 (en) * | 2015-03-17 | 2016-09-21 | Exiris S.r.l. | Cryptophycin-based antibody-drug conjugates with novel self-immolative linkers |
US10975112B2 (en) * | 2015-06-16 | 2021-04-13 | Hangzhou Dac Biotech Co., Ltd. | Linkers for conjugation of cell-binding molecules |
WO2015151079A2 (en) | 2015-06-20 | 2015-10-08 | Hangzhou Dac Biotech Co, Ltd | Auristatin analogues and their conjugates with cell-binding molecules |
-
2017
- 2017-03-02 TW TW112144655A patent/TW202408592A/zh unknown
- 2017-03-02 HU HUE17711475A patent/HUE054726T2/hu unknown
- 2017-03-02 TW TW111125421A patent/TWI825834B/zh active
- 2017-03-02 KR KR1020187028407A patent/KR102445255B1/ko active IP Right Grant
- 2017-03-02 CN CN202111360093.5A patent/CN114191563A/zh active Pending
- 2017-03-02 CN CN202111360563.8A patent/CN114272389B/zh active Active
- 2017-03-02 JP JP2018545210A patent/JP6599019B2/ja active Active
- 2017-03-02 JO JOP/2017/0053A patent/JOP20170053B1/ar active
- 2017-03-02 KR KR1020227022690A patent/KR102456433B1/ko active IP Right Grant
- 2017-03-02 KR KR1020227022691A patent/KR20220101204A/ko not_active Application Discontinuation
- 2017-03-02 KR KR1020247000482A patent/KR20240007722A/ko active IP Right Grant
- 2017-03-02 AU AU2017225982A patent/AU2017225982B2/en active Active
- 2017-03-02 MY MYPI2018001424A patent/MY189113A/en unknown
- 2017-03-02 CN CN202111360555.3A patent/CN114191428A/zh active Pending
- 2017-03-02 ES ES17711475T patent/ES2880402T3/es active Active
- 2017-03-02 IL IL292946A patent/IL292946B1/en unknown
- 2017-03-02 SI SI201730837T patent/SI3423105T1/sl unknown
- 2017-03-02 WO PCT/US2017/020529 patent/WO2017151979A1/en active Application Filing
- 2017-03-02 MX MX2018010562A patent/MX2018010562A/es unknown
- 2017-03-02 PE PE2018001578A patent/PE20181953A1/es unknown
- 2017-03-02 EP EP20204172.9A patent/EP3824909A1/en active Pending
- 2017-03-02 LT LTEP17711475.8T patent/LT3423105T/lt unknown
- 2017-03-02 US US15/448,497 patent/US10548986B2/en active Active
- 2017-03-02 TW TW106106901A patent/TWI772288B/zh active
- 2017-03-02 PL PL17711475T patent/PL3423105T3/pl unknown
- 2017-03-02 MD MDE20190061T patent/MD3423105T2/ro unknown
- 2017-03-02 RU RU2021125492A patent/RU2021125492A/ru unknown
- 2017-03-02 EP EP17711475.8A patent/EP3423105B1/en active Active
- 2017-03-02 SG SG11201806515RA patent/SG11201806515RA/en unknown
- 2017-03-02 PE PE2023001171A patent/PE20231049A1/es unknown
- 2017-03-02 DK DK17711475.8T patent/DK3423105T3/da active
- 2017-03-02 SG SG10202007520WA patent/SG10202007520WA/en unknown
- 2017-03-02 CN CN201780022381.5A patent/CN108883198B/zh active Active
- 2017-03-02 PT PT177114758T patent/PT3423105T/pt unknown
- 2017-03-02 AR ARP170100524A patent/AR107787A1/es unknown
- 2017-03-02 CA CA3013791A patent/CA3013791A1/en active Pending
- 2017-03-02 RS RS20210889A patent/RS62108B1/sr unknown
- 2017-03-02 UA UAA201809739A patent/UA125024C2/uk unknown
- 2017-03-02 RU RU2018134331A patent/RU2754369C2/ru active
- 2017-03-02 BR BR112018067379A patent/BR112018067379A2/pt active Search and Examination
- 2017-03-02 MA MA45280A patent/MA45280B1/fr unknown
- 2017-03-02 PE PE2023001172A patent/PE20231050A1/es unknown
-
2018
- 2018-02-09 US US15/892,921 patent/US10322192B2/en active Active
- 2018-08-16 CO CONC2018/0008667A patent/CO2018008667A2/es unknown
- 2018-08-28 CL CL2018002456A patent/CL2018002456A1/es unknown
- 2018-08-28 IL IL261428A patent/IL261428A/en unknown
- 2018-08-30 PH PH12018501847A patent/PH12018501847A1/en unknown
- 2018-08-31 MX MX2023003806A patent/MX2023003806A/es unknown
- 2018-08-31 MX MX2023003808A patent/MX2023003808A/es unknown
- 2018-08-31 MX MX2023003809A patent/MX2023003809A/es unknown
-
2019
- 2019-10-01 JP JP2019181469A patent/JP6870051B2/ja active Active
- 2019-12-04 US US16/702,720 patent/US20200297860A1/en not_active Abandoned
-
2020
- 2020-05-13 JP JP2020084451A patent/JP2020128413A/ja active Pending
-
2021
- 2021-01-07 CL CL2021000048A patent/CL2021000048A1/es unknown
- 2021-01-07 CL CL2021000049A patent/CL2021000049A1/es unknown
- 2021-02-10 AR ARP210100339A patent/AR121302A2/es unknown
- 2021-02-10 AR ARP210100338A patent/AR121301A2/es unknown
- 2021-04-13 JO JOP/2021/0074A patent/JOP20210074A1/ar unknown
- 2021-04-13 JO JOP/2021/0073A patent/JOP20210073A1/ar unknown
- 2021-07-14 HR HRP20211125TT patent/HRP20211125T1/hr unknown
- 2021-08-02 CY CY20211100686T patent/CY1124628T1/el unknown
- 2021-08-25 JP JP2021137504A patent/JP7254861B2/ja active Active
-
2022
- 2022-12-07 US US18/062,996 patent/US20230398228A1/en active Pending
-
2023
- 2023-03-29 JP JP2023053129A patent/JP2023082096A/ja active Pending
- 2023-12-20 AU AU2023285804A patent/AU2023285804A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR121301A2 (es) | Conjugados de anticuerpos basados en eribulina y métodos de uso | |
CO2019006455A2 (es) | Conjugados anticuerpo-droga para ablación de células madre hematopoyéticas | |
CO2022007924A2 (es) | Conjugados de anticuerpo y fármaco de eribulina anti-mesotelina y métodos de uso | |
CR20160271A (es) | Compuestos peptidométicos y sus conjugados de anticuerpo-fármaco | |
CL2016000468A1 (es) | Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso. | |
NZ741261A (en) | Pyrrolobenzodiazepine antibody drug conjugates and methods of use | |
UY36401A (es) | Conjugados anticuerpos-fármacos | |
UY36862A (es) | Conjugados anticuerpo anti-dll3-fármaco y métodos de uso | |
CO2020016137A2 (es) | Conjugados de anticuerpo modulador de empalme–fármaco y métodos de uso | |
DOP2012000052A (es) | Proteínas terapéuticas de unión a dll4 | |
BR112015027309A2 (pt) | anticorpo, composição, método de tratamento e uso de um anticorpo | |
CO2021006503A2 (es) | Conjugados de anticuerpo–fármaco de herboxidieno y métodos de uso | |
AR120147A1 (es) | Anticuerpos anti-pd-l1 y conjugados anticuerpo-fármaco | |
ECSP21044421A (es) | Anticuerpos anti-pmel17 y conjugados de los mismos | |
UY35250A (es) | Anticuerpos anti-lamp1 y conjugados anticuerpo fármaco, y usos de éstos. | |
UY38265A (es) | Conjugados anticuerpo droga para ablación de células madre hematopoyéticas | |
AR117589A1 (es) | Conjugados de anticuerpo modulador de empalme-fármaco y métodos de uso | |
AR117446A1 (es) | Anticuerpos anti-pmel17 y conjugados de los mismos | |
CO2023008051A2 (es) | Anticuerpos anti-cd48, conjugados de anticuerpo-fármaco, y usos de los mismos | |
EA201991330A1 (ru) | Способы лечения рака с помощью антител к tim-3 | |
AR098781A1 (es) | Compuestos peptidomiméticos y conjugados anticuerpos-droga de los mismos |